[go: up one dir, main page]

WO2005049052A1 - Composition permettant de prevenir et de soulager la xylostomiase, et liqueurs alcoolisees contenant un compose de magnesium et/ou un sel de magnesium - Google Patents

Composition permettant de prevenir et de soulager la xylostomiase, et liqueurs alcoolisees contenant un compose de magnesium et/ou un sel de magnesium Download PDF

Info

Publication number
WO2005049052A1
WO2005049052A1 PCT/KR2004/003015 KR2004003015W WO2005049052A1 WO 2005049052 A1 WO2005049052 A1 WO 2005049052A1 KR 2004003015 W KR2004003015 W KR 2004003015W WO 2005049052 A1 WO2005049052 A1 WO 2005049052A1
Authority
WO
WIPO (PCT)
Prior art keywords
magnesium
group
composition
set forth
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2004/003015
Other languages
English (en)
Inventor
Yong-Geun Kwak
Hyung Sub Kang
Jae-Soon Eun
June-No So
In-Choul Park
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WON GENESIS Corp
Original Assignee
WON GENESIS Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WON GENESIS Corp filed Critical WON GENESIS Corp
Publication of WO2005049052A1 publication Critical patent/WO2005049052A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
    • C12G3/00—Preparation of other alcoholic beverages
    • C12G3/04—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs
    • C12G3/05—Preparation of other alcoholic beverages by mixing, e.g. for preparation of liqueurs with health-improving ingredients, e.g. flavonoids, flavones, polyphenols or polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/334—Foods, ingredients or supplements having a functional effect on health treating the effects of consuming alcohol, narcotics or other addictive behavior, e.g. treating hangover or reducing blood alcohol levels
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/15—Inorganic Compounds
    • A23V2250/156—Mineral combination
    • A23V2250/161—Magnesium

Definitions

  • the present invention relates to a composition for preventing and relieving hangovers, and functional liquor containing one or more ingredients selected from the group consisting of magnesium compounds and magnesium salts.
  • the present invention relates to a composition for preventing and relieving hangover, and a functional alcohol containing one or more ingredients selected from the group consisting of magnesium compounds and magnesium salts.
  • the representative examples of magnesium compounds in according to the present invention are magnesium oxide, magnesium hydroxide and the like.
  • the representative examples of magnesium salts in according to the present invention are magnesium chloride, magnesium sulfate, magnesium citrate, magnesium lactate, magnesium stearate and magnesium gluconate and the like.
  • magnesium oxide and magnesium gluconate are more preferable.
  • the term "a composition for preventing and relieving hangover" as used herein encompasses pharmaceutical compositions, food products, beverages and food additives for such use, i.e., preventing and relieving hangover.
  • composition for preventing and relieving hangover in accordance with the present invention may be administered, usually 1 to 3 times per day, 1 to 2400 mg each time, preferably 10 to 1000 mg each time, based on the magnesium content from the magnesium compounds and/or magnesium salts contained in the composition.
  • the composition for preventing and relieving hangover in accordance with the present invention may contain one or more ingredients selected from the group consisting of magnesium compounds and magnesium salts in an amount of 0.01 to 95% by weight based on the magnesium content.
  • composition for preventing and relieving hangover in accordance with the present invention may also be used in the form of a food additive for such use.
  • the composition of the present invention may be prepared in the form of an additive, adding to various food products.
  • a functional liquor composition refers to a composition containing one or more ingredients selected from the group consisting of magnesium compounds and magnesium salts in an amount of 0.01 to 100 g/L, and preferably 0.1 to 50 g/L in the liquor, based on the magnesium content.
  • the magnesium content may be suitably regulated according to alcohol concentration of the liquor.
  • the above-mentioned liquor includes general liquors such as beer, Soju, whisky and the like, and preferably refers to liquors of which the alcohol concentration is 4 to 50%(v/v).
  • Fig. 1 shows blood alcohol concentration profile over time after a mixture of magnesium gluconate and alcohol was administered orally to rats
  • Fig. 2 shows acetaldehyde concentration in blood profile over time after a mixture of magnesium gluconate and alcohol was administered orally to rats
  • Fig. 3 shows blood concentration profile over time after the mixture of magnesium gluconate and alcohol was administered orally to human beings
  • Fig. 1 shows blood alcohol concentration profile over time after a mixture of magnesium gluconate and alcohol was administered orally to rats
  • Fig. 2 shows acetaldehyde concentration in blood profile over time after a mixture of magnesium gluconate and alcohol was administered orally to rats
  • Fig. 3 shows blood concentration profile over time after the mixture of magnesium gluconate and alcohol was administered orally to human beings
  • Fig. 1 shows blood alcohol concentration profile over time after a mixture of magnesium gluconate and alcohol was administered orally to rats
  • Fig. 2 shows acetaldehyde concentration in blood profile over time after a mixture of
  • FIG. 4 is photographs of stomachs observed with the naked-eye after distilled water (control), magnesium gluconate, ethanol, and ethanol+magnesium gluconate for 7 days were administered to male rats in control and experimental groups, followed by autopsy;
  • Fig. 5 is a bar graph showing feed intake of male rats administered with distilled water (control), magnesium gluconate, ethanol, and ethanol+magnesium gluconate;
  • Fig. 6 is a bar graph showing drinking water intake of male rats administered with distilled water (control), magnesium gluconate, ethanol, and ethanol+magnesium gluconate;
  • Fig. 7 is a bar graph showing changes in body weight of male rats administered with distilled water (control), magnesium gluconate, ethanol, and ethanol+magnesium gluconate.
  • Example 1 Preparation of solution for preventing and relieving hangover Single syrup was mixed in 500 mg of magnesium gluconate and 0.3 ml of diluted hydrochloric acid to be 100 ml so as to prepare a solution for preventing and relieving hangover.
  • Example 2 Preparation of solution for preventing and relieving hangover Single syrup was mixed in 500 mg of magnesium oxide and 0.3 ml of dilute hydrochloric acid to be 100 ml so as to prepare a solution for preventing and relieving hangover.
  • Example 3 Preparation of other preparations A pill, granule, tablet and capsule each comprising 700 mg of magnesium gluconate were prepared according to conventional methods.
  • mice Six male Sprague-Dawley rats, weighing 200 to 250 g, were assigned to each group and used for experiments. Experimental animal groups consisted of the control group in which alcohol were administered to rats, and the group in which alcohol with magnesium gluconate were administered to rats. The rats in the alcohol-administered group were orally administered with 40% ethanol (2g/kg). Whereas, the rats of alcohol with magnesium gluconate-administered group were administered orally with a mixture of 2g/kg of 40% ethanol and 10 mg/kg (based on the magnesium content) of magnesium gluconate. Two hours after administration, animals were suffocated with CO gas, bloods were collected and blood concentrations of alcohol and acetaldehyde were measured.
  • acetaldehyde concentration was measured by HPLC. Measurement of acetaldehyde concentration in blood was performed as follows. One ml of 0.01 M dinitrophenylhydrazine (DNPH) that had been dissolved in 3.6 M HCl, was added to 1 ml of blood. The solution was mixed well at room temperature for 30 min, added 20 ml of pentane and mixed. Then, the resulting mixture was centrifuged at 3,500 rpm for 20 min. The pentane layer thus obtained was washed with 10 ml of distilled water three times, centrifuged again.
  • DNPH dinitrophenylhydrazine
  • anhydrous sodium sulfate Na 2 SO 4 anhydrous
  • the layer was centrifuged to separate the pentane layer, which was then concentrated by an evaporator.
  • the concentrate thus obtained was analyzed quantitatively by HPLC using a mixed solvent of 0.5 ml acetonitrile and distilled water.
  • Novapak C18 (Waters Co.) was used as the column for HPLC, and a mixture of acetonitrile and distilled water (in the ratio of 1:1) was used as the eluent.
  • the retention time of acetaldehyde was 4.95 min.
  • biochemical markers in blood such as glucose, total cholesterol, blood urea nitrogen (BUN), total bilirubin, glutamate-oxalate-transaminase (GOT) and glutamate-pyruvate-transaminase (GPT) determined for each experimental group, there was no significant difference between the magnesium gluconate-administered group and control group. But, GOT and GPT markers were increased in the ethanol-administered group, compared to the control group, and decreased in the ethanol+magnesium gluconate-administered group as compared to the ethanol-administered group (Table 1).
  • * represents significant difference between the ethanol-administered group and control group.
  • P ⁇ 0.05, ** P ⁇ 0.01 represents significant difference between the ethanol+magnesium gluconate- administered group and ethanol-administered group, P ⁇ 0.05 , $ * P ⁇ 0.01
  • the present invention provides a composition for preventing and relieving hangover which is capable of promoting the metabolism of alcohol and acetaldehyde and protecting hepatocytes and gastric parietal cells, thus minimizing side effects of alcohol, and a functional liquor minimizing hangover when taken.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition permettant de prévenir et de soulager la xylostomiase. L'invention concerne également une liqueur fonctionnel contenant un ou plusieurs ingrédients sélectionnés dans le groupe comprenant des composés de magnésium et des sels de magnésium. La composition susmentionnée permet d'activer l'alcool et le métabolisme de l'acétaldéhyde, et de protéger les hépatocytes et les cellules pariétales gastriques, minimisant ainsi les effets secondaires de l'alcool. L'absorption de la liqueur fonctionnelle décrite dans cette invention permet de réduire la xylostomiase.
PCT/KR2004/003015 2003-11-20 2004-11-19 Composition permettant de prevenir et de soulager la xylostomiase, et liqueurs alcoolisees contenant un compose de magnesium et/ou un sel de magnesium Ceased WO2005049052A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20030082685 2003-11-20
KR10-2003-0082685 2003-11-20
KR20040082246 2004-10-14
KR10-2004-0082246 2004-10-14

Publications (1)

Publication Number Publication Date
WO2005049052A1 true WO2005049052A1 (fr) 2005-06-02

Family

ID=34622298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2004/003015 Ceased WO2005049052A1 (fr) 2003-11-20 2004-11-19 Composition permettant de prevenir et de soulager la xylostomiase, et liqueurs alcoolisees contenant un compose de magnesium et/ou un sel de magnesium

Country Status (2)

Country Link
KR (1) KR20050049416A (fr)
WO (1) WO2005049052A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150132410A1 (en) * 2013-11-14 2015-05-14 Michael M. Jacobs Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALTURA B.M ET AL: "Association of alcohol in brain injury, headaches, and stroke with brain-tissue and serum levels of ionized magnesium: a review of recent findings and mechanisms of action", ALCOHOL, vol. 19, no. 2, 1999, pages 119 - 130 *
LINKOLA ET AL: "Adenosine 3', 5' cyclic monophosphate, calcium and magnesium excretion in ethanol intoxication and hangover", ACTA PHYSIOL. SCAND., vol. 107, no. 4, 1979, pages 333 - 337 *
YLINKAHRI ET AL: "Alcohol intoxication and hangover: effects of plasma electrolyte concentrations and acid-base balance", SCAND J. CLIN. LAB. INVEST., vol. 34, no. 4, 1974, pages 327 - 336 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150132410A1 (en) * 2013-11-14 2015-05-14 Michael M. Jacobs Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome

Also Published As

Publication number Publication date
KR20050049416A (ko) 2005-05-25

Similar Documents

Publication Publication Date Title
US9089528B2 (en) Liquid compositions of calcium acetate
US8574633B2 (en) Huperzia serrata (Thunb.) Trev. composition comprising compounded Huperzine A and Huperzine B and methods for preparing it
AU612106B2 (en) Therapeutic composition
CN109893502A (zh) 一种枸橼酸托法替布组合物及其制备方法
JP2001518484A (ja) アルコール中毒者の禁断症状とアルコールに対する渇望を抑制するための、および、健康な人のアルコールの濫用を防ぐための組成物
JP2010059104A (ja) キサンチンオキシダーゼ阻害剤
US4313952A (en) Method of treating acute alcoholic intoxication with pyridoxine P.C.A.
US8367864B2 (en) Dimeric double metal salts of (−)-hydroxycitric acid, methods of making and uses of same
JP4233645B2 (ja) リパーゼ阻害剤
WO2005049052A1 (fr) Composition permettant de prevenir et de soulager la xylostomiase, et liqueurs alcoolisees contenant un compose de magnesium et/ou un sel de magnesium
KR101356330B1 (ko) 간기능 개선제
JP4694132B2 (ja) 内服用液剤、及びグルクロノラクトン含有溶液の味質変化防止液剤
US3928609A (en) Non-alcoholic theophylline product
JP5422370B2 (ja) 経口用液体組成物
JPH08277221A (ja) アルコール吸収抑制剤
JP3228534B2 (ja) 血中アルコール濃度低下用組成物
JP2009274961A (ja) 吸収促進剤
KR101326397B1 (ko) 내복용 액제
CN106102485A (zh) 缓解酒精的有害作用的组合物
JPS61134313A (ja) アルデヒドの毒性抑制剤
KR20060033247A (ko) 마그네슘 화합물 및/또는 마그네슘염과 단삼을 포함하는숙취의 예방 및 해소용 조성물, 및 기능성 주류
JPH059120A (ja) 悪酔改善剤
JP3088707B2 (ja) 吸収抑制剤
KR101268021B1 (ko) 알코올로 인한 홍조 증상 억제용 의약, 식품 또는 음료 조성물
CN120678788A (zh) 唾液酸乳糖穿透血脑屏障向促进老年人大脑健康的用途

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase